Browse > Article
http://dx.doi.org/10.3340/jkns.2020.0135

Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery  

Lee, Min Ho (Department of Neurosurgery, Uijeongbu St. Mary's Hospital, The Catholic University of Korea)
Cho, Kyung-Rae (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Choi, Jung Won (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kong, Doo-Sik (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Seol, Ho Jun (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Nam, Do-Hyun (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Jung, Hyun Ae (Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Sun, Jong-Mu (Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lee, Se-Hoon (Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Ahn, Jin Seok (Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Ahn, Myung-Ju (Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Park, Keunchil (Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lee, Jung-Il (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
Journal of Korean Neurosurgical Society / v.64, no.2, 2021 , pp. 271-281 More about this Journal
Abstract
Objective : Immune checkpoint inhibitors (ICIs) are approved for treating non-small-cell lung cancer (NSCLC); however, the safety and efficacy of combined ICI and Gamma Knife radiosurgery (GKS) treatment remain undefined. In this study, we retrospectively analyzed patients treated with ICIs with or without GKS at our institute to manage patients with brain metastases from NSCLC. Methods : We retrospectively reviewed medical records of patients with brain metastases from NSCLC treated with ICIs between January 2015 and December 2017. Of 134 patients, 77 were assessable for brain responses and categorized into three groups as follows : group A, ICI alone (n=26); group B, ICI with concurrent GKS within 14 days (n=24); and group C, ICI with non-concurrent GKS (n=27). Results : The median follow-up duration after brain metastasis diagnosis was 19.1 months (range, 1-77). At the last follow-up, 53 patients (68.8%) died, 20 were alive, and four were lost to follow-up. The estimated median overall survival (OS) of all patients from the date of brain metastasis diagnosis was 20.0 months (95% confidence interval, 12.5-27.7) (10.0, 22.5, and 42.1 months in groups A, B, and C, respectively). The OS was shorter in group A than in group C (p=0.001). The intracranial disease progression-free survival (p=0.569), local progression-free survival (p=0.457), and complication rates did not significantly differ among the groups. Twelve patients showed leptomeningeal seeding (LMS) during follow-up. The 1-year LMS-free rate in treated with ICI alone group (69.1%) was significantly lower than that in treated with GKS before ICI treatment or within 14 days group (93.2%) (p=0.004). Conclusion : GKS with ICI showed no favorable OS outcome in treating brain metastasis from NSCLC. However, GKS with ICI did not increase the risk of complications. Furthermore, compared with ICI alone, GKS with ICI may be associated with a reduced incidence of LMS. Further understanding of the mechanism, which remains unknown, may help improve the quality of life of patients with brain metastasis.
Keywords
Programmed cell death 1 receptor; Carcinoma, Non-small-cell lung; Radiosurgery; Neoplasm metastasis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. : Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 37 : 1470-1478, 2019   DOI
2 Colaco RJ, Martin P, Kluger HM, Yu JB, Chiang VL : Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg 125 : 17-23, 2016   DOI
3 Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. : Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124 : 687-695, 2014   DOI
4 Weichselbaum RR, Liang H, Deng L, Fu YX : Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 14 : 365-379, 2017   DOI
5 Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. : Five-year follow-up of Nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol 36 : 1675-1684, 2018   DOI
6 Diao K, Bian SX, Routman DM, Yu C, Kim PE, Wagle NA, et al. : Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects. J Neurosurg 129 : 1397-1406, 2018   DOI
7 Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. : Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74 : 5458-5468, 2014   DOI
8 Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, et al. : Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer 125 : 273-281, 2018   DOI
9 Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. : Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 : 2018-2028, 2015   DOI
10 Gavrilovic IT, Posner JB : Brain metastases: epidemiology and pathophysiology. J Neurooncol 75 : 5-14, 2005   DOI
11 Gleissner B, Chamberlain MC : Neoplastic meningitis. Lancet Neurol 5 : 443-452, 2006   DOI
12 Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. : Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17 : 976-983, 2016   DOI
13 Goldberg SB, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R : Durability of brain metastasis response and overall survival in patients with Non-Small Cell Lung Cancer (NSCLC) treated with pembrolizumab. J Clin Oncol 36 : 2009, 2018   DOI
14 Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, et al. : Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 119 : 2754-2764, 2013   DOI
15 Harris S, Chan MD, Lovato JF, Ellis TL, Tatter SB, Bourland JD, et al. : Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer. Int J Radiat Oncol Biol Phys 83 : e53-e59, 2012   DOI
16 Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. : Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 : 1540-1550, 2016   DOI
17 Hodge JW, Guha C, Neefjes J, Gulley JL : Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) 22 : 1064-1084, 2008
18 Johnson AG, Ruiz J, Hughes R, Page BR, Isom S, Lucas JT, et al. : Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget 6 : 18945-18955, 2015   DOI
19 Kanai O, Fujita K, Okamura M, Nakatani K, Mio T : Severe exacerbation or manifestation of primary disease related to Nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases. Ann Oncol 27 : 1354-1356, 2016   DOI
20 Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al. : Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92 : 368-375, 2015   DOI
21 Grossman SA, Krabak MJ : Leptomeningeal carcinomatosis. Cancer Treat Rev 25 : 103-119, 1999   DOI
22 Lee MH, Kong DS, Seol HJ, Nam DH, Lee JI : The influence of biomarker mutations and systemic treatment on cerebral metastases from NSCLC treated with radiosurgery. J Korean Neurosurg Soc 60 : 21-29, 2017   DOI
23 Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL : Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117 : 227-233, 2012   DOI
24 Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. : Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17 : 1497-1508, 2016   DOI
25 Lee HY, Ahn HK, Jeong JY, Kwon MJ, Han JH, Sun JM, et al. : Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. Lung Cancer 79 : 40-45, 2013   DOI
26 Lehrer EJ, Peterson J, Brown PD, Sheehan JP, Quinones-Hinojosa A, Zaorsky NG, et al. : Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international metaanalysis of individual patient data. Radiother Oncol 130 : 104-112, 2019   DOI
27 Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. : Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16 : 5664-5678, 2010   DOI
28 Lu VM, Goyal A, Rovin RA, Lee A, McDonald KL : Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radio-surgery for metastatic brain disease: a systematic review and metaanalysis. J Neurooncol 141 : 1-12, 2019   DOI
29 Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, et al. : Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 5 : e1057388, 2016   DOI
30 Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, et al. : Management of brain metastases in tyrosine kinase inhibitornaive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol 35 : 1070-1077, 2017   DOI
31 Bidoli P, Chiari R, Catino A, Grossi F, Noberasco C, Gelsomino F, et al. : Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy. Ann Oncol 27(suppl 6) : 1228P, 2016
32 Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. : 24-month overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 14 : 124-129, 2019   DOI
33 Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH, et al. : Ipilimumab and stereotactic radiosurgery versus stereotactic radio-surgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol 40 : 444-450, 2017   DOI
34 Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, et al. : Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 23 : 191-195, 2013   DOI
35 Murphy B, Walker J, Bassale S, Monaco D, Jaboin J, Ciporen J, et al. : Concurrent radiosurgery and immune checkpoint inhibition. Am J Clin Oncol 42 : 253-257, 2019   DOI
36 Pardoll DM : The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 : 252-264, 2012   DOI
37 Qian JM, Yu JB, Kluger HM, Chiang VL : Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 122 : 3051-3058, 2016   DOI
38 Remon J, Le Rhun E, Besse B : Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era. Cancer Treat Rev 53 : 128-137, 2017   DOI
39 Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. : Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer. N Engl J Med 373 : 123-135, 2015   DOI
40 Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. : Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 : 1627-1639, 2015   DOI
41 Cho KR, Lee MH, Kong DS, Seol HJ, Nam DH, Sun JM, et al. : Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer. J Neurooncol 125 : 331-338, 2015   DOI
42 Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. : Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 : 255-265, 2017   DOI
43 Schapira E, Hubbeling H, Yeap BY, Mehan WA Jr, Shaw AT, Oh K, et al. : Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases. Int J Radiat Oncol Biol Phys 101 : 624-629, 2018   DOI
44 Brahmer JR, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. : Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol 18 : 1600-1609, 2017   DOI
45 Chamberlain MC : Leptomeningeal metastasis. Curr Opin Oncol 22 : 627-635, 2010   DOI
46 Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, et al. : Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys 100 : 916-925, 2018   DOI
47 Choi YL, Sun JM, Cho J, Rampal S, Han J, Parasuraman B, et al. : EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One 8 : e56011, 2013   DOI
48 Sorensen JB, Hansen HH, Hansen M, Dombernowsky P : Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 6 : 1474-1480, 1988   DOI
49 Shepard MJ, Xu Z, Donahue J, Eluvathingal Muttikkal TJ, Cordeiro D, Hansen L, et al. : Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study. J Neurosurg 133 : 611-946, 2020   DOI
50 Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD : Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2 : 899-906, 2013   DOI
51 Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, et al. : A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85 : 1312-1318, 2013   DOI